Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Astellas to “Seek Every Opportunity” for Domestic Vaccine Business, Including Alliances with Foreign Companies
August 6, 2012
- Astellas’s Sales Down 3.3% in April-June Due to Competition with Generics
August 6, 2012
- Takeda to Exclusively Distribute 7 J&J OTC Brands in Japan
August 6, 2012
- Eisai’s April-June Sales, Profits Show Double-Digit Decrease by NHI Price Reduction of Aricept
August 6, 2012
- Sanofi Pasteur Not Planning to Follow Request to Cut IPV Price: President Triomphe
August 3, 2012
- Eisai: Domestic Sales of Aricept Down 6% on Volume Basis, to Target 90 Billion Yen through Patient Campaign
August 3, 2012
- Shionogi Files NDA for Lipodystrophy Treatment based on Data from Investigator-Initiated Trial
August 3, 2012
- DSP to Establish Sales Force for Anticancer Drugs in North America
August 3, 2012
- Rebamipide Is Most Frequently Prescribed Drug by Generic Name: Apollo Medical Survey
August 3, 2012
- Daiichi Sankyo: April-June Nexium Sales 6% of Full-Year Target, Set to Boost Promotion after Lifting of Long-Term Prescription Ban
August 2, 2012
- Otsuka Files for Additional Indication for Samsca for Fluid Retention with Liver Cirrhosis
August 2, 2012
- BMKK, Pfizer Promote Disease Education on Chronic Hepatitis B
August 2, 2012
- Shionogi Launches Endoxan Powder Aimed at Pediatric Patients
August 2, 2012
- AnGes MG to Initiate Domestic PI/II Trials for Collategene
August 2, 2012
- Torii Initiates PII/PIII Clinical Studies in Japan for Desensitization Therapy for House Dust Mite Induced Allergies
August 2, 2012
- Daiichi Sankyo’s Apr-Jun Sales Up 4.7%, Bolstered by Ranbaxy
August 1, 2012
- Iwasaki of Takeda Shows Confidence in Achieving Sales Target of Nesina with Rapid Growth
August 1, 2012
- Astellas, Tokyo Institute of Technology to Start Joint Drug Discovery Research for Neglected Tropical Diseases
July 31, 2012
- Shionogi Files NDA for Fixed-Dose Combination of Irbetan, Fluitran
July 31, 2012
- Nycomed Drives Up Takeda’s April-June Sales by 11.5%, but Operating Profits Decline
July 31, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…